Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, surgical-robot specialist Intuitive Surgical (Nasdaq: ISRG) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Intuitive's business and see what CAPS investors are saying about the stock right now.

Intuitive facts

Headquarters (Founded) Sunnyvale, Calif. (1995)
Market Cap $11.33 billion
Industry Health care equipment
Trailing-12-Month Revenue $1.35 billion

CEO Dr. Gary Guthart (since 2010)

CFO Marshall Mohr (since 2006)

Return on Equity (Average, Past 3 Years) 18.8%
Cash/Debt $980.9 million / $0

Boston Scientific (NYSE: BSX)

Medtronic (NYSE: MDT)

St. Jude Medical (NYSE: STJ)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 95% of the 4,021 members who have rated Intuitive believe the stock will outperform the S&P 500 going forward. These bulls include beppaun and dumberthanafool.

Late last year, beppaun noted that Intuitive "has a clean balance sheet with no debt outstanding, has increasing free cash flow and is currently at the low end of EV/FCF valuation in the last 5 years." Our CAPS member concludes: "With the opportunity to grow international revenues and a buyback program in place there should be a nice margin of safety."

Fools remain attracted to Intuitive's dominant position in robotics-assisted surgery, rock-solid financials, and new procedure opportunities for its revolutionary da Vinci system. Over the next five years, Intuitive Surgical is even expected to grow its bottom line (24.7% per annum) at a substantially faster pace than medical-device specialists Boston Scientific (8.1%), Medtronic (8.8%), and St. Jude (12.3%), as well as a diversified health-care giants like Johnson & Johnson (NYSE: JNJ) (5.9%) and Abbott Labs (NYSE: ABT) (9.1%).

CAPS member dumberthanafool elaborates on the bull case:

Part A -- Macro: I believe the combination of demographic trends, bad habits, and bad incentives strongly favor growth in medical spending, regardless of our efforts to control it. This is true throughout the developing world. If I'm right, [Intuitive] will benefit from this. Part B: Micro -- [Intuitive] has an amazing product, is a first mover in the industry, has patent protection, and has a switching cost/sunk cost moat. Part C: Larger Picture -- I am coming to the conclusion that dividend stocks are, as crazy as this sounds, overvalued in comparison to growth stocks.

What do you think about Intuitive, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Intuitive is a Motley Fool Rule Breakers recommendation. Johnson & Johnson is an Inside Value and Income Investor choice. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Medtronic and Johnson & Johnson. Motley Fool Alpha owns shares of Johnson & Johnson and Abbott. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.